A Population‐Based Meta‐Analysis of Plasma Glial Fibrillary Acidic Protein for Cognitive Decline and Incident Dementia

Expression of glial fibrillary acidic protein (GFAP), a marker of reactive astrocytosis, co‐localizes with neuropathology in the brain. Blood‐derived levels of GFAP have been associated with cognitive decline and dementia status. However, further examinations at a population‐based level are necessary to broaden generalizability and assess the biomarker’s potential efficacy in community settings.